SnapD plus CGM to help adults with type 2 diabetes and overweight manage blood sugar

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, controlled pilot at Ramathibodi Hospital comparing the SnapD mobile app alone, SnapD combined with a Linx CGM, and standard of care over an 8‑week period. SnapD uses Gemini 2.5 Flash to recognize Thai dishes, estimate nutritional values, and link meal entries with glucose patterns from CGM to provide personalized feedback. Participants are adults 18–65 with type 2 diabetes, BMI >23 kg/m², HbA1c 6.5–9%, and must keep antidiabetic medication doses stable during the study. Outcomes focus on short‑term changes in glycemic control and usability of the AI tool in a Thai dietary context.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 18 to 65 years, male or female at birth
2. Diagnosed with type 2 Diabetes Mellitus with overweight or obesity (BMI\>23 kg/m²)
3. Hemoglobin A1c (HbA1c) 6.5-9% measured within 3 months prior to the screening date
4. Willing to maintain their current antidiabetic medication regimen without dose adjustment for the entire 8-week study duration
5. Must possess an internet-enabled devices e.g. smartphone, tablet compatible with the SnapD application
6. Able and willing to adhere intervention, including using snapD and CGM

Exclusion Criteria:

1. Currently pregnant, plan pregnancy or breastfeeding during the 8-week study period
2. Current participation in another interventional clinical trial
3. Current use of insulin or incretin-based therapies (e.g., GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists)
4. Presence of severe hearing or visual impairment that, in the investigator's judgment, would preclude the participant from safely and effectively using the SnapD application or the CGM device
5. known contraindication to CGM usage e.g., a history of severe hypersensitivity to the device's materials or adhesive, planing to go on CT-contrasted imaging etc.

Where it's running

• Department of Medicine, Ramathibodi Hospital,
  Bangkok, Bangkok, Thailand Recruiting

Study contacts

• Principal investigator: Supasuta Wongdama — Ramathibodi Hospital
• Study coordinator: Supasuta Wongdama, MD
• Email: supasuta.won@gmail.com
• Phone: +6690-575-4190

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aleniglipron for adults with overweight/obesity and type 2 diabetes

  A long-term test to see if aleniglipron helps weight loss and blood sugar control in adults who are overweight or obese and have type 2 diabetes.

  Recruiting at 57 sites Phase 3 Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Birmingham, Alabama and 73 other locations · NCT07654374

• ONO-3310 safety test in healthy men and adults with CKD and type 2 diabetes

  This early-phase study tests whether ONO-3310 is safe and well tolerated in healthy Japanese men and in adults with chronic kidney disease and type 2 diabetes, using single and multiple oral doses.

  Recruiting Phase 1 Ono Pharmaceutical Co., Ltd. · Fukuoka, Fukuoka · NCT07619157

• Effects of Henagliflozein on liver fat in patients with diabetes and fatty liver disease

  This study is testing if a new diabetes medication called Henagliflozein can help reduce liver fat in people with type 2 diabetes and fatty liver disease.

  Recruiting Phase 4 Zhujiang Hospital · Guangzhou, Guangdong · NCT06449833

• Testosterone Undecanoate's effects on liver fat in overweight men with diabetes

  This study is testing if a testosterone treatment can help reduce liver fat in overweight men with type 2 diabetes and low testosterone levels.

  Recruiting Phase 4 Medical University of Vienna · Vienna · NCT03851627

• Investigating brain health in youth at risk for type 2 diabetes

  This study is trying to see how being overweight or having blood sugar issues affects brain health in kids aged 12-17 who might be at risk for type 2 diabetes.

  Recruiting at 2 sites Washington University School of Medicine · St Louis, Missouri and 1 other locations · NCT05277558

• Effects of SGLT2 Inhibitors and Ketones on Heart and Muscle Health

  This study is testing if a diabetes medication can change ketone levels in people with Type 2 Diabetes and heart failure to see how it affects their heart and muscle health over 12 weeks.

  Recruiting Early Phase 1 The University of Texas Health Science Center at San Antonio · San Antonio, Texas · NCT05057806

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.